TMO DCF Analysis: Intrinsic Value $421 vs Price $658

gurufocus.com · 2026-10-12

On October 12, 2026, we conducted a DCF analysis for Thermo Fisher Scientific Inc (TMO), a company that has shown notable price performance over the past year,

TickrTrends take: TMO currently trades at a significant premium to its discounted cash flow derived intrinsic value, suggesting the market has priced in substantial growth expectations or other factors beyond traditional cash flow analysis. For valuation-focused investors, the gap between the DCF estimate and current market price indicates that near-term catalysts or narrative shifts could be relevant to monitoring, particularly given TickrTrends' assessment that the stock is fairly valued within the Healthcare sector context. The relationship between these valuation metrics suggests investors should track whether TMO's operational performance and forward guidance can justify the current premium pricing.

Read the full story at gurufocus.com →